Insider Selling: Relay Therapeutics (NASDAQ:RLAY) Insider Sells 4,508 Shares of Stock

Key Points

• Insider sale: Peter Rahmer sold 4,508 Relay Therapeutics shares at an average price of $20.03, generating $90,295.24. He retained 223,657 shares after the transaction.
• Stock and earnings: RLAY recently traded at $18.77, while the company reported a quarterly loss of $0.41 per share, missing analyst expectations of a $0.39 loss; revenue also fell short of estimates.
• Analyst outlook: Several analysts raised their price targets to approximately $30–$31, and the stock carries a consensus “Moderate Buy” rating with an average target of $25.92.

Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) insider Peter Rahmer sold 4,508 shares of Relay Therapeutics stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $20.03, for a total transaction of $90,295.24. Following the sale, the insider owned 223,657 shares of the company's stock, valued at approximately $4,479,849.71. The trade was a 1.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Peter Rahmer also recently made the following trade(s):

• On Tuesday, July 28th, Peter Rahmer sold 748 shares of Relay Therapeutics stock. The stock was sold at an average price of $18.61, for a total transaction of $13,920.28.
• On Tuesday, June 30th, Peter Rahmer sold 50,000 shares of Relay Therapeutics stock. The stock was sold at an average price of $19.09, for a total transaction of $954,500.00.

Relay Therapeutics Stock Performance

NASDAQ RLAY traded down $0.65 on Friday, reaching $18.77. 2,762,681 shares of the company's stock traded hands, compared to its average volume of 3,169,067. The firm has a market cap of $4.11 billion, a price-to-earnings ratio of -11.96 and a beta of 1.69. The stock has a 50 day moving average price of $19.21 and a 200-day moving average price of $14.71. Relay Therapeutics, Inc. has a fifty-two week low of $3.52 and a fifty-two week high of $21.27.

Relay Therapeutics (NASDAQ:RLAY - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.02). The business had revenue of $0.35 million for the quarter, compared to the consensus estimate of $0.96 million. As a group, equities research analysts anticipate that Relay Therapeutics, Inc. will post -1.61 EPS for the current fiscal year.

Institutional Trading of Relay Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of RLAY. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Relay Therapeutics during the 2nd quarter worth about $784,000. California State Teachers Retirement System boosted its holdings in Relay Therapeutics by 1,726.3% in the 2nd quarter. California State Teachers Retirement System now owns 3,179,652 shares of the company's stock worth $59,491,000 after buying an additional 3,005,553 shares during the last quarter. Frazier Life Sciences Management L.P. purchased a new stake in Relay Therapeutics during the 2nd quarter worth approximately $19,004,000. Susquehanna Fundamental Investments LLC purchased a new stake in Relay Therapeutics during the 2nd quarter worth approximately $366,000. Finally, Moore Capital Management LP acquired a new position in shares of Relay Therapeutics during the second quarter valued at approximately $7,746,000. Hedge funds and other institutional investors own 96.98% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. The Goldman Sachs Group upped their price objective on Relay Therapeutics from $22.00 to $31.00 and gave the stock a "buy" rating in a research report on Tuesday, July 21st. Barclays boosted their target price on shares of Relay Therapeutics from $27.00 to $30.00 and gave the company an "overweight" rating in a research note on Friday, August 7th. JPMorgan Chase & Co. raised their price target on shares of Relay Therapeutics from $28.00 to $31.00 and gave the company an "overweight" rating in a research report on Friday, August 14th. Citigroup reaffirmed a "market outperform" rating on shares of Relay Therapeutics in a report on Monday, August 10th. Finally, Wall Street Zen downgraded shares of Relay Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $25.92.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company's core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source